Compare
Oragenics Inc vs Medicus Pharma Ltd. vs Korsana Biosciences, Inc. vs Genprex, Inc.
| Latest fiscal year | Oragenics Inc OGEN | Medicus Pharma Ltd. MDCX | Korsana Biosciences, Inc. KRSA | Genprex, Inc. GNPX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | $2.07M | n/a |
| Revenue growth (YoY) | n/a | n/a | +3.7% | n/a |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/a | -239.8% | n/a |
| Net margin | n/a | n/a | -170.1% | n/a |
| Net income | -$9.84M | -$47.28M | -$3.53M | -$16.23M |
| EPS (Diluted) | -$4.56 | -$2.74 | -$1.11 | n/a |
| Operating cash flow | -$9.25M | -$22.78M | -$3.31M | -$15.31M |
| Free cash flow | n/a | n/a | n/a | n/a |
| Cash & equivalents | $4.40M | $8.71M | $3.24M | $7.83M |
| Total assets | $10.07M | $10.06M | $9.98M | $10.16M |
| Total liabilities | $1.79M | $10.02M | n/a | $2.20M |
| Shareholders' equity | $8.28M | $37.3K | $9.09M | $7.96M |
| Return on year-end equity | -118.9% | n/m | -38.8% | -203.8% |
| Shares outstanding | 4.27M | 25.18M | 3.82M | 3.29M |
Revenue, most recent five fiscal years
| Fiscal year | Oragenics Inc | Medicus Pharma Ltd. | Korsana Biosciences, Inc. | Genprex, Inc. |
|---|---|---|---|---|
| Latest | $37.7K Ended 2023-12-31 | n/a | $2.07M Ended 2025-12-31 | $0 Ended 2024-12-31 |
| 1 year earlier | $131.5K Ended 2022-12-31 | n/a | $2.00M Ended 2024-12-31 | $0 Ended 2023-12-31 |
| 2 years earlier | $87.0K Ended 2021-12-31 | n/a | $0 Ended 2023-12-31 | $0 Ended 2022-12-31 |
| 3 years earlier | n/a | n/a | $297.0K Ended 2022-12-31 | $0 Ended 2021-12-31 |
| 4 years earlier | n/a | n/a | $3.94M Ended 2021-12-31 | $0 Ended 2020-12-31 |